Characterisation Of Two Novel Markers Of Osteosarcoma Metastasis As Potential Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$624,500.00
Summary
Osteosarcoma (OS) is the most common bone tumour in children and adolescents. In spite of aggressive chemotherapy, OS tumours that metastasise to the lungs result in dismal long-term survivals of only 10-20%. For these patients, new treatment options are desperately needed. In this proposal we show compelling data identifying two new markers of OS metastasis. This research aims to validate the suitability of these novel markers as therapeutic targets to prevent OS metastasis.
Development Of A Novel Drug For Chronic And Infected Wounds
Funder
National Health and Medical Research Council
Funding Amount
$482,362.00
Summary
Chronic wounds affect more than 9 million people worldwide and demand for wound care is increasing. The annual cost to healthcare systems in the US and Australia in treating such wounds is US$25 billion and AU$3 billion, respectively, and there is urgent need for more effective approaches.
Mitochondrially targeted anti-cancer drugs modulate the mitochondrial genome. Successful cancer management requires novel therapeutical approaches. This project will test the effect of a new class of compounds that target mitochondria, the powerhouse of the cells, where they suppress expression of mitochondrial genes. By this mechanism, cancers that are resistant to apoptosis induction can be inhibited.
Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.
A new Src, PKCdelta and Akt regulated protease activated receptor system in metastasis. In contrast with localised cancer which can often be cured, curative treatment is generally not possible for cancer that has spread. This project will characterise a protein that drives the spread of cancer and to develop new approaches to treat patients at risk of developing these aggressive tumours that spread to other organs.
Heparan sulphate mimetics: Versatile tools for chemical biology. This project aims to develop chemical tools to study heparan sulphate-binding proteins. Heparan sulphate is a complex polysaccharide that is ubiquitously expressed on mammalian cells and interacts with proteins to mediate numerous biological and pathological functions. These interactions are poorly understood. This project will use homogeneous, structurally defined compounds to study heparan sulphate and its binding partners in bio ....Heparan sulphate mimetics: Versatile tools for chemical biology. This project aims to develop chemical tools to study heparan sulphate-binding proteins. Heparan sulphate is a complex polysaccharide that is ubiquitously expressed on mammalian cells and interacts with proteins to mediate numerous biological and pathological functions. These interactions are poorly understood. This project will use homogeneous, structurally defined compounds to study heparan sulphate and its binding partners in biology. This is expected to lead to a better, molecular-level understanding of these fundamental processes, and may have future applications in biotechnology and drug development.Read moreRead less
KLK4 Is A Master Regulator Of Tumour Microenvironment Remodelling In Prostate Cancer And Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$596,305.00
Summary
The current biomarker for prostate cancer, PSA, belongs to a large family of related proteins called KLK enzymes. We have evidence that one of these enzymes, KLK4, regulates many different pathways involved in tumour spreading especially to bones. This project will determine the specific components involved with a view to finding better biomarkers of tumour spread and bone metastasis and designing better treatments for these aspects of the disease.
Characterisation and improvement of radiation beams used for radiotherapy of small lesions. This project aims to characterise the radiation dose from a medical linear accelerator after the beam has been shaped by a mini-multileaf collimator. The characterisation will be achieved through a combination of computer simulations and experimental investigation of the beam using the technique of three-dimensional gel dosimetry. When the dosage characteristics are known, techniques will be developed to ....Characterisation and improvement of radiation beams used for radiotherapy of small lesions. This project aims to characterise the radiation dose from a medical linear accelerator after the beam has been shaped by a mini-multileaf collimator. The characterisation will be achieved through a combination of computer simulations and experimental investigation of the beam using the technique of three-dimensional gel dosimetry. When the dosage characteristics are known, techniques will be developed to improve radiotherapy treatments in patients with small lesions with sizes of up to a few centimetres. This will lead to an improved outcome for some cancer patients.Read moreRead less
Development of therapeutic agents that target carbonic anhydrase enzymes. This research will discover new chemical entities (compounds) that may lead to therapies for the treatment of cancer, glaucoma and malaria. The research underpins a mechanism to add value to our compounds before partnering with industry to transform the discoveries made here to deliverable therapies that could benefit the health of millions, thus offering a potentially high value contribution to the Australian economy. The ....Development of therapeutic agents that target carbonic anhydrase enzymes. This research will discover new chemical entities (compounds) that may lead to therapies for the treatment of cancer, glaucoma and malaria. The research underpins a mechanism to add value to our compounds before partnering with industry to transform the discoveries made here to deliverable therapies that could benefit the health of millions, thus offering a potentially high value contribution to the Australian economy. The experience and commitment of the multi-disciplinary network of researchers offers exceptional training and employment opportunities for tomorrow's scientists in techniques for discovery and characterisation of novel chemicals, and their interaction with disease targets.Read moreRead less
Chemical proteomics: proteomics with no detection limit. Half of all drugs are derived from natural products, yet little is known about how most achieve their therapeutic action. This project aims to develop a methodology to rapidly uncover drug-protein interactions and pave the way for faster drug development and a better understanding of drug action.